GET DAILY SIGNALSGuardian Pharmacy Services (GRDN) Consolidates After -9.8% Pullback From September Highs
Key Takeaways
- Guardian Pharmacy Services (GRDN) traded near $40 in late October 2026, roughly 10% below its mid-September peak as the stock cooled off after a sharp rally.
- Over the trailing 30 days, shares pulled back about 9.8% from the September 21 close of $44.16, keeping the stock in consolidation territory rather than a breakout.
- Guardian is one of the nation's largest long-term care (LTC) pharmacy services providers, serving approximately 210,000 residents across 38 states.
- Second-quarter 2026 revenue rose 2% year over year to $351.8 million, with residents served up 8%, and management raised its full-year guidance.
- Acquisitions such as the Nautilus Pharmacy transaction and Inflation Reduction Act (IRA) drug-pricing dynamics remain central swing factors for the stock.
Where GRDN Stands in the Market Right Now
Guardian Pharmacy Services shares have been consolidating after a rapid upward move. The stock climbed from the mid-$30s in early September 2026 to an intraday peak near $48 by mid-September, before giving back much of those gains through October. As of late October 2026, GRDN traded near $39.83, down about 9.8% from the September 21 closing level of $44.16.
The pullback reflects a broader normalization following a momentum-driven advance rather than a change in the company's underlying fundamentals. Guardian operates in a relatively defensive corner of healthcare, serving residents of assisted living facilities, skilled nursing facilities, and behavioral health communities. This positioning has historically provided steadier, less cyclical demand compared with more discretionary parts of the economy, though the stock's recent volatility shows that short-term trading sentiment can still outweigh the steady business backdrop. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Guardian Pharmacy Services (GRDN) Business Overview and Competitive Position
Guardian Pharmacy Services, based in Atlanta, is a leading technology-enabled long-term care pharmacy services company. Through a locally operated business model backed by a centralized corporate team, Guardian delivers medications and a suite of clinical and data-analytics services designed to improve medication adherence, reduce the cost of care, and improve outcomes for residents of long-term care facilities.
The company has a differentiated focus on historically lower-acuity settings, particularly assisted living facilities and behavioral health communities, where it acts as a preferred pharmacy provider. Its proprietary GuardianShield platform offers specialized programs that support accuracy, safety, and efficiency. Guardian's scale provides purchasing leverage and a cost advantage over smaller independent pharmacies, while its local, high-touch service model distinguishes it from larger institutional competitors. As of mid-2026, the company operated a growing network of roughly 60 licensed pharmacies serving about 210,000 residents, supported by both organic growth and a disciplined acquisition strategy.
Recent Developments Driving GRDN
Several verified developments have shaped investor sentiment around GRDN in recent months. In August 2026, the company reported second-quarter results showing revenue of $351.8 million, up 2% year over year, while residents served grew 8% to approximately 210,000. Net income reached $22.1 million, including an $8.5 million settlement related to a payor dispute, and adjusted EBITDA rose to $29.7 million. Management raised its full-year guidance and noted that, excluding Inflation Reduction Act-related pricing reductions, revenue growth would have been in the low double digits.
The company also continues to execute on its acquisition pipeline. In early September 2026, Guardian announced the acquisition of assets from Tennessee-based Nautilus Pharmacy, which serves assisted living communities across 14 states. The transaction transitions Nautilus-served residents to existing Guardian pharmacies, leveraging the company's local pharmacy network while adding new community partners. These developments reinforce the growth narrative, even as IRA-driven pricing pressure continues to weigh on reported revenue growth and, at times, investor sentiment. From what I see, the acquisition activity adds a constructive layer to the story.
2026 Outlook and What Investors Should Watch
Looking ahead, investors are likely to focus on Guardian's ability to sustain volume and resident growth while managing the financial impact of IRA-related pricing changes. The company's next quarterly earnings release will be closely watched for updates on revenue growth, adjusted EBITDA expansion, and any revision to full-year guidance, particularly given management's commentary that underlying growth remains strong once IRA pricing reductions are excluded.
Additional factors to monitor include the pace and integration of acquisitions, resident adoption rates within assisted living communities, and reimbursement dynamics across Medicare Part D and commercial payors. Broader demographic trends, including the aging U.S. population, provide a long-term demand tailwind for long-term care pharmacy services, while competitive pressure from national and regional providers and potential regulatory changes remain key risks. As always, these are areas to watch for context rather than a basis for any specific investment decision. I’m watching this closely for how the company navigates the pricing environment.
Exploring Tickeron’s Trending AI Robots
In my research process, I often review Tickeron’s Trending AI Robots page to get a sense of how AI-driven bots are performing across various strategies and timeframes. It offers a curated look at top bots that trade thousands of tickers, helping me explore systematic approaches without replacing my own analysis. This resource has proven useful for understanding automated signals in equities like those in the healthcare space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GRDN in downward trend: price dove below 50-day moving average on October 21, 2026
GRDN moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend. In 14 of 18 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GRDN moved out of overbought territory on September 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 12 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRDN as a result. In 29 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for GRDN turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 14 similar instances when the indicator turned negative. In 8 of the 14 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
The 10-day moving average for GRDN crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for GRDN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 17 of 18 cases where GRDN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +6.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRDN advanced for three days, in 118 of 138 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. GRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.053) is normal, around the industry mean (204.137). P/E Ratio (37.124) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (2.023) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement